It isn’t just old people who are “vulnerable to chemotherapy toxicity.” Everyone suffers collateral damage when they undergo chemotherapy. I’m not just talking about the short-term side effects that people associate with chemotherapy such as hair loss and nausea. I’m talking about heart, brain and nerve damage. Common side effects that the majority of multiple myeloma patients suffer from.
I know. I was first diagnosed with multiple myeloma when I was 36 back in 1994. I was strong and otherwise healthy. Yet the chemotherapy regimens I underwent during ’95-’96 left me with short, long-term and late stage side effects. Some of these side effects healed. Some didn’t. Some side effects got worse over time.
Practically speaking, MMers must think long-term. Studies show that achieving complete or very-good partial remission is not required for a long overall survival. Meaning your induction therapy is probably going to be the first chemo regimen of several over the next decade or two.
There is a solution. Evidence-based Integrative therapies to enhance the efficacy of your chemo. Evidence-based, anti-MM nutrition, supplementation and lifestyle therapies.
The article linked and excerpted below talks about a chemo regimen for newly diagnosed MMers called VCD-Lite that is effective but should be used only for older folks who are too frail to withstand higher doses of chemotherapy.
Multiple Myeloma at a glance. Click the image below-
The solution is not rocket science. I’m not talking about some sort of “ancient Chinese secret.” The induction chemotherapy “VCD-Lite” discussed below combined with the Multiple Myeloma Cancer Coaching Program will mean effective MM management with a LOT LESS toxicity.
Have you been diagnosed with MM? What symptoms are you experiencing? Scroll down the page, post a question or a comment and I will reply to you ASAP. Click the link on the right side of the page to watch the free webinar about the MM CC Program.
“Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma…
“With the high and increasing proportion of patients with multiple myeloma being very old and/or otherwise vulnerable to chemotherapy toxicity, it is increasingly important to determine the best regimens for treating these patients, yet existing clinical studies largely miss that mark by focusing on younger, fitter patients,”
“The best regimens maximize the likelihood of multiple myeloma control, ie, efficacy, while minimizing risk of severe toxicity…
“Meanwhile, regarding current clinical practice we recognize recent studies that have shown that induction regimens that incorporate both proteasome inhibitors and immunomodulatory agents are likely the emerging standard of care for newly diagnosed myeloma,” the researchers wrote. “As a result, off protocol we frequently employ the dose-reduced lenalidomide, bortezomib, dexamethasone (‘RVD-lite’) for patients willing to come for once weekly bortezomib.””